Obinutuzumab plus bendamustine in rituximab-refractory indolent lymphoma

被引：2
|
作者：
Hamlin, Paul A. [1 ,2 ,3 ]
机构：
[1] Mem Sloan Kettering Canc Ctr, Basking Ridge Med Oncol Serv, New York, NY 10065 USA
[2] Mem Sloan Kettering Canc Ctr, Lymphoma Serv, Div Hematol Oncol, Dept Med, New York, NY 10065 USA
[3] New York Presbyterian Hosp, Dept Med, Weill Cornell Med Coll, New York, NY 10032 USA
来源：
LANCET ONCOLOGY | 2016年 / 17卷 / 08期
关键词：
D O I：
10.1016/S1470-2045(16)30157-7
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：1023 / 1025
页数：4
相关论文
共 50 条
  • [21] Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
    Dennie, Trevor W.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2290 - 2311
  • [22] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    REVISTA CHILENA DE LITERATURA, 2024, (109): : 1194 - 1205
  • [23] Polatuzumab vedotin plus bendamustine and rituximab or obinutuzumab in relapsed/refractory follicular lymphoma: a phase Ib/II study
    Flowers, Christopher R.
    Matasar, Matthew J.
    Herrera, Alex F.
    Hertzberg, Mark
    Assouline, Sarit
    Demeter, Judit
    Mcmillan, Andrew
    Mehta, Amitkumar
    Opat, Stephen
    Trneny, Marek
    Musick, Lisa
    Hirata, Jamie
    Yang, Annie
    Sehn, Laurie H.
    HAEMATOLOGICA, 2024, 109 (04) : 1194 - 1205
  • [24] COST-EFFECTIVENESS OF BENDAMUSTINE VERSUS IBRITUMOMAB TIUXETAN IN THE TREATMENT OF RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN'S LYMPHOMA IN CANADA
    Lachaine, J.
    Beauchemin, C.
    Mathurin, K.
    Aissa, F.
    VALUE IN HEALTH, 2013, 16 (03) : A141 - A142
  • [25] Introduction: Treatment of patients with rituximab-refractory indolent non-hodgkin's lymphoma
    Gregory, Stephanie A.
    SEMINARS IN HEMATOLOGY, 2007, 44 (03) : S1 - S1
  • [26] Bendamustine plus rituximab for indolent B-cell lymphoma of renal significance
    Ribes, David
    Hachem, Helene E. L.
    Oberic, Lucie
    Vergez, Francois
    Delas, Audrey
    Belliere, Julie
    Protin, Caroline
    Kamar, Nassim
    Ferrandiz, Ines
    Tavitian, Suzanne
    Laurent, Camille
    Huart, Antoine
    Chauveau, Dominique
    Ysebaert, Loic
    Faguer, Stanislas
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (03) : 356 - 362
  • [27] Bendamustine Is Effective Therapy in Patients With Rituximab-Refractory, Indolent B-cell Non-Hodgkin Lymphoma Results From a Multicenter Study
    Kahl, Brad S.
    Bartlett, Nancy L.
    Leonard, John P.
    Chen, Ling
    Ganjoo, Kristen
    Williams, Michael E.
    Czuczman, Myron S.
    Robinson, K. Sue
    Joyce, Robin
    van der Jagt, Richard H.
    Cheson, Bruce D.
    CANCER, 2010, 116 (01) : 106 - 114
  • [28] The novel alkylator bendamustine HCI is active in both rituximab-refractory and rituximab-sensitive relapsed indolent NHL with acceptable toxicity.
    Cohen, P
    Cheson, B
    Friedberg, J
    Robinson, KS
    Foran, J
    Fayad, L
    Tulpule, A
    Bessudo, A
    van der Jagt, R
    Suster, MS
    Multani, PS
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 576S - 576S
  • [29] Outcomes of Patients with Indolent Lymphoma Treated with Bendamustine Plus Rituximab Compared to Rituximab Plus CVP or CHOP Chemoimmunotherapy in Ontario
    Suleman, Adam
    Aktar, Suriya
    Liu, Ning
    Chan, Kelvin
    Cheung, Matthew
    Prica, Anca
    BLOOD, 2021, 138
  • [30] Outcomes of patients with indolent lymphoma treated with bendamustine plus rituximab compared to rituximab plus CVP or CHOP chemoimmunotherapy in Ontario
    Suleman, Adam
    Aktar, Suriya J. J.
    Ante, Zharmaine
    Liu, Ning
    Chan, Kelvin K. W.
    Cheung, Matthew C. C.
    Prica, Anca
    BRITISH JOURNAL OF HAEMATOLOGY, 2023, 202 (06) : 1104 - 1118
12345